Core Laboratories Lowers Q1 Guidance Amid Middle East Instability
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy CLB?
Source: seekingalpha
- Guidance Downgrade: Core Laboratories (CLB) has lowered its Q1 earnings guidance due to instability in the Middle East, projecting earnings of $0.05-$0.07 per share and revenues between $119 million and $123 million, both below analyst expectations of $0.13 EPS and $127.5 million in revenue, indicating market concerns about the company's future performance.
- Operating Income Forecast: The company anticipates operating income in the range of $5.7 million to $7.1 million for Q1, a significant drop from last month's forecast of $9.7 million to $12.2 million, reflecting the direct impact of changing client activity levels on its operations, particularly in its Reservoir Description segment.
- Business Impact Intensified: The unique role of Core in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization has made its Reservoir Description business particularly vulnerable, as these activities depend on predictable field access, sample movement, and laboratory operations, leading to operational challenges.
- Market Reaction: Following the guidance downgrade, Core Laboratories' stock fell 4.7% in after-hours trading, reflecting investor concerns about the company's ability to maintain profitability in an uncertain market environment, which may affect its future investment appeal.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLB
Wall Street analysts forecast CLB stock price to fall
1 Analyst Rating
0 Buy
0 Hold
1 Sell
Moderate Sell
Current: 16.210
Low
11.50
Averages
11.50
High
11.50
Current: 16.210
Low
11.50
Averages
11.50
High
11.50
About CLB
Core Laboratories Inc. is a provider of proprietary and patented reservoir description and production enhancement services and products for the oil and gas industry. The Company helps to evaluate and improve reservoir performance and increase oil and gas recovery from new and existing fields. It makes measurements of reservoir rocks, reservoir fluids (crude oil, natural gas and water) and their derived products. It assists clients in evaluating subsurface targets associated with carbon capture and sequestration projects or initiatives. Its segments include Reservoir Description, which provides laboratory-based analytical and field services to characterize the properties of crude oil and crude oil-derived products for the oil and gas industry, and Production Enhancement segment, which provides integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions aimed at increasing the effectiveness of enhanced oil recovery projects.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Core Laboratories Lowers Q1 Guidance Amid Middle East Instability
- Guidance Downgrade: Core Laboratories (CLB) has lowered its Q1 earnings guidance due to instability in the Middle East, projecting earnings of $0.05-$0.07 per share and revenues between $119 million and $123 million, both below analyst expectations of $0.13 EPS and $127.5 million in revenue, indicating market concerns about the company's future performance.
- Operating Income Forecast: The company anticipates operating income in the range of $5.7 million to $7.1 million for Q1, a significant drop from last month's forecast of $9.7 million to $12.2 million, reflecting the direct impact of changing client activity levels on its operations, particularly in its Reservoir Description segment.
- Business Impact Intensified: The unique role of Core in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization has made its Reservoir Description business particularly vulnerable, as these activities depend on predictable field access, sample movement, and laboratory operations, leading to operational challenges.
- Market Reaction: Following the guidance downgrade, Core Laboratories' stock fell 4.7% in after-hours trading, reflecting investor concerns about the company's ability to maintain profitability in an uncertain market environment, which may affect its future investment appeal.
See More
CORE LABORATORIES INC - PROJECTS Q1 2026 REVENUE AND EARNINGS TO FALL SHORT OF PREVIOUS GUIDANCE
- Revenue Expectations: Core Laboratories anticipates Q1 2026 revenue and earnings to be below previous guidance.
- Removal of Extraneous Terms: The company has removed the term "Lab" from its communications to streamline its messaging.
See More
CORE LABORATORIES INC: UPDATED Q1 2026 GUIDANCE REVISED TO A RANGE OF $119 MILLION TO $123 MILLION
Core Laboratories Revised Guidance: Core Laboratories has updated its guidance for the first quarter of 2026.
Revenue Range Adjustment: The revised revenue range is projected to be between $119 million and $123 million.
See More
CORE LABORATORIES INC - Q1 2026 EPS (EX-ITEMS) PROJECTIONS BETWEEN $0.05 AND $0.07
Core Laboratories Inc. Overview: The company is involved in various projects and is focused on enhancing its operational capabilities.
Earnings Per Share (EPS): The projected EPS for Q1 2026 is estimated to be between $0.05 and $0.07.
See More
Core Laboratories Declares Quarterly Dividend of $0.01
- Quarterly Dividend Declaration: Core Laboratories has declared a quarterly dividend of $0.01 per share, maintaining consistency with previous dividends, which reflects the company's stability in the current economic environment.
- Dividend Yield: The forward yield of this dividend stands at 0.2%, indicating the company's ongoing commitment to shareholder returns while also suggesting a healthy cash flow situation.
- Payment Schedule: The dividend will be payable on March 9, with a record date of February 16 and an ex-dividend date of February 13, providing investors with a clear timeline that aids in their investment decisions.
- Historical Performance Context: Core Laboratories' dividend policy aligns with its historical earnings data, demonstrating the company's continued efforts in providing technology to replace tier-1 oil inventory, thereby enhancing its competitive position in the industry.
See More
Core Laboratories Q4 Earnings Exceed Expectations
- Earnings Beat: Core Laboratories reported a Q4 non-GAAP EPS of $0.21, surpassing expectations by $0.02, indicating robust profitability and boosting investor confidence in the company's financial health.
- Significant Revenue Growth: The company achieved Q4 revenue of $138.3 million, a 7.0% year-over-year increase, exceeding analyst expectations by $7.9 million, showcasing Core Laboratories' strong performance amid recovering market demand and solidifying its market position.
- Technology Replacement Potential: Core Laboratories is focused on providing technology to replace tier-1 oil inventory, and as the global energy transition accelerates, the adoption of this technology is expected to create new growth opportunities and enhance its competitive edge in the industry.
- Positive Future Outlook: The earnings beat not only reflects current market performance but also lays a foundation for sustained growth, attracting increased investor interest as demand for efficient energy solutions rises.
See More
Core Laboratories Lowers Q1 Guidance Amid Middle East Instability
- Guidance Downgrade: Core Laboratories (CLB) has lowered its Q1 earnings guidance due to instability in the Middle East, projecting earnings of $0.05-$0.07 per share and revenues between $119 million and $123 million, both below analyst expectations of $0.13 EPS and $127.5 million in revenue, indicating market concerns about the company's future performance.
- Operating Income Forecast: The company anticipates operating income in the range of $5.7 million to $7.1 million for Q1, a significant drop from last month's forecast of $9.7 million to $12.2 million, reflecting the direct impact of changing client activity levels on its operations, particularly in its Reservoir Description segment.
- Business Impact Intensified: The unique role of Core in supporting regional client studies, crude oil assay testing, and reservoir rock and fluid characterization has made its Reservoir Description business particularly vulnerable, as these activities depend on predictable field access, sample movement, and laboratory operations, leading to operational challenges.
- Market Reaction: Following the guidance downgrade, Core Laboratories' stock fell 4.7% in after-hours trading, reflecting investor concerns about the company's ability to maintain profitability in an uncertain market environment, which may affect its future investment appeal.
See More
CORE LABORATORIES INC - PROJECTS Q1 2026 REVENUE AND EARNINGS TO FALL SHORT OF PREVIOUS GUIDANCE
- Revenue Expectations: Core Laboratories anticipates Q1 2026 revenue and earnings to be below previous guidance.
- Removal of Extraneous Terms: The company has removed the term "Lab" from its communications to streamline its messaging.
See More
CORE LABORATORIES INC: UPDATED Q1 2026 GUIDANCE REVISED TO A RANGE OF $119 MILLION TO $123 MILLION
Core Laboratories Revised Guidance: Core Laboratories has updated its guidance for the first quarter of 2026.
Revenue Range Adjustment: The revised revenue range is projected to be between $119 million and $123 million.
See More
CORE LABORATORIES INC - Q1 2026 EPS (EX-ITEMS) PROJECTIONS BETWEEN $0.05 AND $0.07
Core Laboratories Inc. Overview: The company is involved in various projects and is focused on enhancing its operational capabilities.
Earnings Per Share (EPS): The projected EPS for Q1 2026 is estimated to be between $0.05 and $0.07.
See More
Core Laboratories Declares Quarterly Dividend of $0.01
- Quarterly Dividend Declaration: Core Laboratories has declared a quarterly dividend of $0.01 per share, maintaining consistency with previous dividends, which reflects the company's stability in the current economic environment.
- Dividend Yield: The forward yield of this dividend stands at 0.2%, indicating the company's ongoing commitment to shareholder returns while also suggesting a healthy cash flow situation.
- Payment Schedule: The dividend will be payable on March 9, with a record date of February 16 and an ex-dividend date of February 13, providing investors with a clear timeline that aids in their investment decisions.
- Historical Performance Context: Core Laboratories' dividend policy aligns with its historical earnings data, demonstrating the company's continued efforts in providing technology to replace tier-1 oil inventory, thereby enhancing its competitive position in the industry.
See More
Core Laboratories Q4 Earnings Exceed Expectations
- Earnings Beat: Core Laboratories reported a Q4 non-GAAP EPS of $0.21, surpassing expectations by $0.02, indicating robust profitability and boosting investor confidence in the company's financial health.
- Significant Revenue Growth: The company achieved Q4 revenue of $138.3 million, a 7.0% year-over-year increase, exceeding analyst expectations by $7.9 million, showcasing Core Laboratories' strong performance amid recovering market demand and solidifying its market position.
- Technology Replacement Potential: Core Laboratories is focused on providing technology to replace tier-1 oil inventory, and as the global energy transition accelerates, the adoption of this technology is expected to create new growth opportunities and enhance its competitive edge in the industry.
- Positive Future Outlook: The earnings beat not only reflects current market performance but also lays a foundation for sustained growth, attracting increased investor interest as demand for efficient energy solutions rises.
See More
